• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Signaling Pathways >> Chromatin/Epigenetics >> PARP >> Iniparib (BSI-201)
Related Products
Iniparib (BSI-201)PARP1 inhibitor,intravenously adminsitered

Iniparib (BSI-201)

Catalog No. A4157
Size Price Stock Qty
10mM (in 1mL DMSO) $50.00 In stock
10mg $75.00 In stock
50mg $230.00 In stock
200mg $650.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

Iniparib (BSI-201)

Biological Activity

Description Iniparib (BSI-201) is an intravenously administered inhibitor of PARP1
Targets PARP1          

Iniparib (BSI-201) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Iniparib (BSI-201) Molarity Calculator



Chemical Properties

Cas No. 160003-66-7 SDF Download SDF
Synonyms BSI201,BSI 201
Chemical Name 4-iodo-3-nitrobenzamide
Canonical SMILES C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
Formula C7H5IN2O3 M.Wt 292.03
Solubility >83.3mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


Iniparib, previously named BSI-201, is an intravenously administered PARP1 inhibitor, which either alone or in combination with chemotherapy, has important antitumor activity in studies in vitro and in vivo. It is active against a broad range of cancer cells in culture, including drug resistant cell lines. Iniparib has been reported to be a prodrug whose C-nitroso metabolite, 4-iodo-3-nitrosobenzamide, selectively kills tumor cells by oxidizing the zinc finger of PARP-1 resulting in ejection of zinc and inhibition of PARP activity.


Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs. 2010 Sep;13(9):646-56.

Xuesong Liu, Yan Shi, David X. Maag, Joann P. Palma, Melanie J. Patterson, Paul A. Ellis, Bruce W. Surber, Damien B. Ready, Niru B. Soni, Uri S. Ladror, Allison J. Xu, Ramesh Iyer, John E. Harlan, Larry R. Solomon, Cherrie K. Donawho, Thomas D. Penning, Eric F. Johnson,  Alexander R. Shoemaker. Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor. Clinical Cancer Research. January 15, 2012 18; 510.

S. Kopetz, M. M. Mita, I. Mok, K. K. Sankhala, J. Moseley, B. M. Sherman, C. R. Bradley and A. W. Tolcher. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. Journal of Clinical Oncology. (Meeting Abstracts) May 2008 vol. 26 no. 15_suppl 3577